scholarly journals PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation

Stroke ◽  
2015 ◽  
Vol 46 (10) ◽  
pp. 2926-2934 ◽  
Author(s):  
Sheetal Bodhankar ◽  
Yingxin Chen ◽  
Andrew Lapato ◽  
Abby L. Dotson ◽  
Jianming Wang ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Nervous System ◽  
Ischemic Stroke ◽  
Central Nervous System Inflammation

scholarly journals A cell-based drug delivery platform for treating central nervous system inflammation

2021 ◽  
Author(s):  
Oren Levy ◽  
Veit Rothhammer ◽  
Ivan Mascanfroni ◽  
Zhixiang Tong ◽  
Rui Kuai ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Inflammation ◽  
Delivery Platform ◽  
A Cell

scholarly journals Central Nervous System Agents for Ischemic Stroke: Neuroprotection Mechanisms

2011 ◽  
Vol 11 (2) ◽  
pp. 81-97 ◽  
Author(s):  
Rachna S. Pandya ◽  
Lijuan Mao ◽  
Hua Zhou ◽  
Shuanhu Zhou ◽  
Jiang Zeng ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Ischemic Stroke ◽  
Central Nervous System Agents

scholarly journals Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials

2010 ◽  
Vol 2010 ◽  
pp. 1-8 ◽  
Author(s):  
Peter A. Walker ◽  
Matthew T. Harting ◽  
Shinil K. Shah ◽  
Mary-Clare Day ◽  
Ramy El Khoury ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Ischemic Stroke ◽  
Cell Therapy ◽  
Progenitor Cell ◽  
Neurological Injury ◽  
Cell Therapies ◽  
Potential Efficacy ◽  
Cord Injury

Recent preclinical work investigating the role of progenitor cell therapies for central nervous system (CNS) injuries has shown potential neuroprotection in the setting of traumatic brain injury (TBI), spinal cord injury (SCI), and ischemic stroke. Mechanisms currently under investigation include engraftment and transdifferentiation, modulation of the locoregional inflammatory milieu, and modulation of the systemic immunologic/inflammatory response. While the exact mechanism of action remains controversial, the growing amount of preclinical data demonstrating the potential benefit associated with progenitor cell therapy for neurological injury warrants the development of well-controlled clinical trials to investigate therapeutic safety and efficacy. In this paper, we review the currently active or recently completed clinical trials investigating the safety and potential efficacy of bone marrow-derived progenitor cell therapies for the treatment of TBI, SCI, and ischemic stroke. Our review of the literature shows that while the preliminary clinical trials reviewed in this paper offer novel data supporting the potential efficacy of stem/progenitor cell therapies for CNS injury, a great deal of additional work is needed to ensure the safety, efficacy, and mechanisms of progenitor cell therapy prior to widespread clinical trials.

scholarly journals Viral pre-challenge increases central nervous system inflammation after intracranial interleukin-1β injection

2014 ◽  
Vol 11 (1) ◽  
Author(s):  
Yvonne Couch ◽  
Andrew E Davis ◽  
Inês Sá-Pereira ◽  
Sandra J Campbell ◽  
Daniel C Anthony
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Interleukin 1Β ◽  
Central Nervous System Inflammation

A novel monoclonal antibody that recognizes human perivascular cells of the central nervous system under a specific immune reaction

2000 ◽  
Vol 20 (3) ◽  
pp. 216-220 ◽  
Author(s):  
Hideaki Yokoo ◽  
Koji Isoda ◽  
Mizuaki Sakura ◽  
Atsushi Sasaki ◽  
Junko Hirato ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Nervous System ◽  
Immune Reaction ◽  
Perivascular Cells ◽  
The Central Nervous System
Sign in / Sign up

Export Citation Format

Share Document